-
1
-
-
0036923412
-
Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer
-
Cai X, Chen P, Yin X, Li Q. Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2002;5(6):427-8.
-
(2002)
Zhongguo Fei Ai Za Zhi
, vol.5
, Issue.6
, pp. 427-428
-
-
Cai, X.1
Chen, P.2
Yin, X.3
Li, Q.4
-
2
-
-
34247855822
-
A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly
-
Chen YM, Perng RP, Tsai CM, Whang-Peng J. A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly. Journal of Thoracic Oncology 2006;1(2):141-5.
-
(2006)
Journal of Thoracic Oncology
, vol.1
, Issue.2
, pp. 141-145
-
-
Chen, Y.M.1
Perng, R.P.2
Tsai, C.M.3
Whang-Peng, J.4
-
3
-
-
84857376291
-
British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine (1250mg/msup2/sup) combined with cisplatin 50 mg/msup2/sup (GC50) versus cisplatin 80 mg/msup2/sup (GC80) versus carboplatin AUC 6 (GCb6) in advanced NSCLC
-
Ferry D, Billingham L, Jarrett H, Dunlop D, Thompson J, Kumar M, et al. British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine (1250mg/msup2/sup) combined with cisplatin 50 mg/msup2/sup (GC50) versus cisplatin 80 mg/msup2/sup (GC80) versus carboplatin AUC 6 (GCb6) in advanced NSCLC. Thorax 2011;66:A41.
-
(2011)
Thorax
, vol.66
, pp. 41
-
-
Ferry, D.1
Billingham, L.2
Jarrett, H.3
Dunlop, D.4
Thompson, J.5
Kumar, M.6
-
4
-
-
0042413836
-
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group
-
Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology 2003;21(16):3016-24.
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.16
, pp. 3016-3024
-
-
Fossella, F.1
Pereira, J.R.2
von Pawel, J.3
Pluzanska, A.4
Gorbounova, V.5
Kaukel, E.6
-
5
-
-
0038460705
-
Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer
-
Mazzanti P, Massacesi C, Rocchi MB, Mattioli R, Lippe P, Trivisonne R, et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2003;41(1):81-9.
-
(2003)
Lung Cancer
, vol.41
, Issue.1
, pp. 81-89
-
-
Mazzanti, P.1
Massacesi, C.2
Rocchi, M.B.3
Mattioli, R.4
Lippe, P.5
Trivisonne, R.6
-
6
-
-
0036810227
-
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
-
Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology 2002;13(10):1539-49.
-
(2002)
Annals of Oncology
, vol.13
, Issue.10
, pp. 1539-1549
-
-
Rosell, R.1
Gatzemeier, U.2
Betticher, D.C.3
Keppler, U.4
Macha, H.N.5
Pirker, R.6
-
7
-
-
0037050352
-
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
-
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine 2002;346(2):92-8.
-
(2002)
New England Journal of Medicine
, vol.346
, Issue.2
, pp. 92-98
-
-
Schiller, J.H.1
Harrington, D.2
Belani, C.P.3
Langer, C.4
Sandler, A.5
Krook, J.6
-
8
-
-
0035889915
-
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma
-
Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001;92(10):2639-47.
-
(2001)
Cancer
, vol.92
, Issue.10
, pp. 2639-2647
-
-
Sweeney, C.J.1
Zhu, J.2
Sandler, A.B.3
Schiller, J.4
Belani, C.P.5
Langer, C.6
-
9
-
-
85041838981
-
A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non-small cell lung cancer
-
Yan D, Wang G, Zhang G, Hu C. A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2001;4(3):188-90.
-
(2001)
Zhongguo Fei Ai Za Zhi
, vol.4
, Issue.3
, pp. 188-190
-
-
Yan, D.1
Wang, G.2
Zhang, G.3
Hu, C.4
-
10
-
-
0042661285
-
Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial
-
Zatloukal P, Petruzelka L, Zemanová M, Kolek V, Skricková J, Pesek M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003;41(3):321-31.
-
(2003)
Lung Cancer
, vol.41
, Issue.3
, pp. 321-331
-
-
Zatloukal, P.1
Petruzelka, L.2
Zemanová, M.3
Kolek, V.4
Skricková, J.5
Pesek, M.6
-
11
-
-
0034978657
-
Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non-small cell lung cancer: interim analysis
-
Belani C, TAX 326 Study Group. Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non-small cell lung cancer: interim analysis. Seminars in Oncology 2001;28(3):10-4.
-
(2001)
Seminars in Oncology
, vol.28
, Issue.3
, pp. 10-14
-
-
Belani, C.1
-
12
-
-
0036333477
-
Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer
-
Belani CP, TAX 326 Study Group. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Seminars in Oncology 2002;29(3):4-9.
-
(2002)
Seminars in Oncology
, vol.29
, Issue.3
, pp. 4-9
-
-
Belani, C.P.1
-
13
-
-
33745893529
-
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial
-
Belani CP, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer 2006;53(2):231-9.
-
(2006)
Lung Cancer
, vol.53
, Issue.2
, pp. 231-239
-
-
Belani, C.P.1
Pereira, J.R.2
von Pawel, J.3
Pluzanska, A.4
Gorbounova, V.5
Kaukel, E.6
-
14
-
-
0000845015
-
Docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCb) versus vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC): results of a multicenter, randomized phase III study
-
Fossella F. Docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCb) versus vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC): results of a multicenter, randomized phase III study. European Journal of Cancer 2001;37:S154.
-
(2001)
European Journal of Cancer
, vol.37
, pp. S154
-
-
Fossella, F.1
-
15
-
-
0000905275
-
Randomized pan-European trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC)
-
Gatzemeier U, Rosell R, Betticher D, Keppler U, Macha H, Pirker R, et al. Randomized pan-European trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC). European Journal of Cancer 1999;35(4):S246.
-
(1999)
European Journal of Cancer
, vol.35
, Issue.4
, pp. S246
-
-
Gatzemeier, U.1
Rosell, R.2
Betticher, D.3
Keppler, U.4
Macha, H.5
Pirker, R.6
-
16
-
-
85041857526
-
Randomized multicenter trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC): results of a planned interim analysis
-
(abstract 1789)
-
Macha HN, Gatzemeier U, Betticher DC, Keppler U, Berthet P, Chemaissan A, et al. Randomized multicenter trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC): results of a planned interim analysis. Proceedings of the American Society of Clinical Oncology. Los Angeles, 1998; Vol. 17:465a (abstract 1789).
-
(1998)
Proceedings of the American Society of Clinical Oncology. Los Angeles
, vol.465
, pp. 17
-
-
Macha, H.N.1
Gatzemeier, U.2
Betticher, D.C.3
Keppler, U.4
Berthet, P.5
Chemaissan, A.6
-
17
-
-
85041853504
-
Gemcitabine-cisplatin (GP) vs gemcitabine-carboplatin (GC) in advanced non-small cell lung cancer (ANSCLC): a multicenter phase II randomized trial of a 21-day schedule. Preliminary results
-
(abstract 2125)
-
Mazzanti P, Lippe P, Battelli N, Mattioli R, Buzzi F, Trivisonne R, et al. Gemcitabine-cisplatin (GP) vs gemcitabine-carboplatin (GC) in advanced non-small cell lung cancer (ANSCLC): a multicenter phase II randomized trial of a 21-day schedule. Preliminary results. Proceedings of the American Society of Clinical Oncology. New Orleans: American Society of Clinical Oncology, 2000; Vol. 19:540a (abstract 2125).
-
(2000)
Proceedings of the American Society of Clinical Oncology. New Orleans: American Society of Clinical Oncology
, vol.540
, pp. 19
-
-
Mazzanti, P.1
Lippe, P.2
Battelli, N.3
Mattioli, R.4
Buzzi, F.5
Trivisonne, R.6
-
18
-
-
0011343790
-
Gemcitabine-cisplatin (GP) vs gemcitabine-carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a multicenter phase II randomized trial
-
Mazzanti P, Massacesi C, Mattioli R, Trivisonne R, Buzzi F, De Signoribus G, et al. Gemcitabine-cisplatin (GP) vs gemcitabine-carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a multicenter phase II randomized trial. European Journal of Cancer. Lisbon: European Journal of Cancer, 2001; Vol. 37 Suppl 6:S50.
-
(2001)
European Journal of Cancer. Lisbon: European Journal of Cancer
, vol.37
, pp. S50
-
-
Mazzanti, P.1
Massacesi, C.2
Mattioli, R.3
Trivisonne, R.4
Buzzi, F.5
De Signoribus, G.6
-
19
-
-
0003268464
-
Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients with stage IIIB and IV non-small lung cancer (NSCLC): final results of Czech Lung Cancer Co-operative Group phase III randomized trial
-
abstract
-
Novakova L, Petruzelka L, Zemanova M, Kolek V, Grygarkova I, Sixtova D, et al. Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients with stage IIIB and IV non-small lung cancer (NSCLC): final results of Czech Lung Cancer Co-operative Group phase III randomized trial. Proceedings of the American Society of Clinical Oncology. 2002; Vol. 21 Part 1:abstract 1225.
-
(2002)
Proceedings of the American Society of Clinical Oncology
, vol.21
, pp. 1225
-
-
Novakova, L.1
Petruzelka, L.2
Zemanova, M.3
Kolek, V.4
Grygarkova, I.5
Sixtova, D.6
-
20
-
-
34250731320
-
Results of Polish medical centres within an international randomized phase III study of docetaxel plus cisplatin and docetaxel plus carboplatin versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer
-
Ramlau R, Pluzanska A, Szczesna A, Karnicka-Mlodkowska H, Wojtukiewicz M, Oklek K, et al. Results of Polish medical centres within an international randomized phase III study of docetaxel plus cisplatin and docetaxel plus carboplatin versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer. Journal of Oncology 2007;57(2):146-52.
-
(2007)
Journal of Oncology
, vol.57
, Issue.2
, pp. 146-152
-
-
Ramlau, R.1
Pluzanska, A.2
Szczesna, A.3
Karnicka-Mlodkowska, H.4
Wojtukiewicz, M.5
Oklek, K.6
-
21
-
-
0000012871
-
A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer
-
Rodriguez J, Pawel J, Pluzanska A, Gorbounova V, Fossella F, Kaukel E, et al. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer. Proceedings of the American Society of Clinical Oncology. 2001; Vol. 20:314a.
-
(2001)
Proceedings of the American Society of Clinical Oncology
, vol.20
, pp. 314
-
-
Rodriguez, J.1
Pawel, J.2
Pluzanska, A.3
Gorbounova, V.4
Fossella, F.5
Kaukel, E.6
-
22
-
-
85041814497
-
Cancer facts & figures 2010
-
(accessed 26 June
-
American Cancer Society. Cancer facts & figures 2010. www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-and-figures-2010 (accessed 26 June 2013).
-
(2013)
-
-
-
23
-
-
34347379142
-
Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis
-
Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. Journal of the National Cancer Institute 2007;99(11):847-57.
-
(2007)
Journal of the National Cancer Institute
, vol.99
, Issue.11
, pp. 847-857
-
-
Ardizzoni, A.1
Boni, L.2
Tiseo, M.3
Fossella, F.V.4
Schiller, J.H.5
Paesmans, M.6
-
24
-
-
74949133978
-
American Society of Clinical Oncology clinical practice guideline: update on chemotherapy for stage IV non-small-cell lung cancer
-
Azzoli CG, Baker S Jr, Temin S, Pao W, AliffT, Brahmer J, et al. American Society of Clinical Oncology clinical practice guideline: update on chemotherapy for stage IV non-small-cell lung cancer. Journal of Clinical Oncology 2009;27(36):6251-66.
-
(2009)
Journal of Clinical Oncology
, vol.27
, Issue.36
, pp. 6251-6266
-
-
Azzoli, C.G.1
Baker, S.2
Temin, S.3
Pao, W.4
Aliff, T.5
Brahmer, J.6
-
25
-
-
34548436008
-
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis
-
Baggstrom M, Stinchcombe T, Fried D, Poole C, Hensing T, Socinski M. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. Journal of Thoracic Oncology 2007;2(9):845-53.
-
(2007)
Journal of Thoracic Oncology
, vol.2
, Issue.9
, pp. 845-853
-
-
Baggstrom, M.1
Stinchcombe, T.2
Fried, D.3
Poole, C.4
Hensing, T.5
Socinski, M.6
-
27
-
-
57849117384
-
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
-
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009;45(2):228-47.
-
(2009)
European Journal of Cancer
, vol.45
, Issue.2
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
Schwartz, L.H.4
Sargent, D.5
Ford, R.6
-
28
-
-
33750603100
-
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database
-
Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. Journal of Clinical Oncology 2006;24(28):4539-44.
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.28
, pp. 4539-4544
-
-
Govindan, R.1
Page, N.2
Morgensztern, D.3
Read, W.4
Tierney, R.5
Vlahiotis, A.6
-
30
-
-
84872417999
-
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated September 2011
-
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
-
(2011)
The Cochrane Collaboration
-
-
Higgins, J.P.T.1
Green, S.2
-
31
-
-
5444235920
-
Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer
-
Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 2004;22(19):3852-9.
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.19
, pp. 3852-3859
-
-
Hotta, K.1
Matsuo, K.2
Ueoka, H.3
Kiura, K.4
Tabata, M.5
Tanimoto, M.6
-
32
-
-
34548022868
-
A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer
-
Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2007;57(3):348-58.
-
(2007)
Lung Cancer
, vol.57
, Issue.3
, pp. 348-358
-
-
Jiang, J.1
Liang, X.2
Zhou, X.3
Huang, R.4
Chu, Z.5
-
33
-
-
85041843347
-
Common toxicity criteria
-
(accessed 26 June
-
National Cancer Institute. Common toxicity criteria. ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf (accessed 26 June 2013).
-
(2013)
National Cancer Institute
-
-
-
34
-
-
84971581087
-
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
-
NSCLC Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311(7010):899-909.
-
(1995)
BMJ
, vol.311
, Issue.7010
, pp. 899-909
-
-
-
35
-
-
9144243571
-
Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial
-
Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 2004;43(1):83-91.
-
(2004)
Lung Cancer
, vol.43
, Issue.1
, pp. 83-91
-
-
Paccagnella, A.1
Favaretto, A.2
Oniga, F.3
Barbieri, F.4
Ceresoli, G.5
Torri, W.6
-
36
-
-
0032583387
-
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints
-
Parmar MKB, Valter T, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
-
(1998)
Statistics in Medicine
, vol.17
, pp. 2815-2834
-
-
Parmar, M.K.B.1
Valter, T.2
Stewart, L.3
-
37
-
-
0016799829
-
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
-
Pocock S, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
-
(1975)
Biometrics
, vol.31
, pp. 103-115
-
-
Pocock, S.1
Simon, R.2
-
38
-
-
77951473661
-
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
-
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology 2010;21(9):1804-9.
-
(2010)
Annals of Oncology
, vol.21
, Issue.9
, pp. 1804-1809
-
-
Reck, M.1
von Pawel, J.2
Zatloukal, P.3
Ramlau, R.4
Gorbounova, V.5
Hirsh, V.6
-
39
-
-
85041800343
-
Pharmacology of cancer chemotherapy
-
In: DeVita VT, Lawrence TS, Rosenberg SA editor(s). 7th Edition. Philadelphia: Lippincott Williams & Wilkins
-
Reed E. Pharmacology of cancer chemotherapy. In: DeVita VT, Lawrence TS, Rosenberg SA editor(s). Cancer: Principles and Practice of Oncology. 7th Edition. Philadelphia: Lippincott Williams & Wilkins, 2005:419-26.
-
(2005)
Cancer: Principles and Practice of Oncology
, pp. 419-426
-
-
Reed, E.1
-
40
-
-
84870318976
-
Review Manager
-
5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration
-
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager. 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
-
(2011)
-
-
-
41
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine 2006;355(24):2542-50.
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.24
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
-
42
-
-
49049089802
-
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
-
Scagliotti V, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology 2008;26:3543-51.
-
(2008)
Journal of Clinical Oncology
, vol.26
, pp. 3543-3551
-
-
Scagliotti, V.1
Parikh, P.2
von Pawel, J.3
Biesma, B.4
Vansteenkiste, J.5
Manegold, C.6
-
44
-
-
0035106967
-
Estimation of glomerular filtration rate in cancer patients
-
Wright J, Boddy A, Highley M, Fenwick J, McGill A, Calvert A. Estimation of glomerular filtration rate in cancer patients. British Journal of Cancer 2001;84(4):452-9.
-
(2001)
British Journal of Cancer
, vol.84
, Issue.4
, pp. 452-459
-
-
Wright, J.1
Boddy, A.2
Highley, M.3
Fenwick, J.4
McGill, A.5
Calvert, A.6
|